NextCell Pharma publishes its Interim Report 3 2024/2025

Third Quarter (2025-03-01 to 2025-05-31)

• Operating income amounted to 2,262 (2,482) TSEK, of which Cellaviva contributed 2,261 (2,442) TSEK.
   
• Net sales amounted to 2,261 (2,442) TSEK.
   
• Profit/loss after financial items amounted to -10,271 (-8,822) TSEK.
   
• Earnings per share* were -0.14 (-0.26) SEK.
   
• Cash and cash equivalents amounted to 16,710 (20,797) TSEK. 
   
• Equity ratio** amounted to 79 (77) percent.

First Nine Months (2024-09-01 to 2025-05-31)

• Operating income amounted to 8,542 (9,582) TSEK, of which Cellaviva contributed 8,338 (9,022) TSEK.
   
• Net sales amounted to 8,338 (9,022) TSEK.
   
• Profit/loss after financial items amounted to -26,511 (-28,710) TSEK.
   
• Earnings per share* were -0.36 (-0.84) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the third quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first nine months  of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 31 May 2025: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the third quarter

● At the end of March, NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been elected to the Board of Directors of ATMP Sweden.

● At the beginning of April, NextCell published preliminary 1-year results from the older age group (12–21 years) in the ongoing ProTrans-Young clinical study. The study evaluates the safety and efficacy of the company's cell therapy ProTrans in preserving insulin production in young individuals with newly diagnosed type 1 diabetes, compared to placebo.

● NextCell announced in early April that Dr. Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the international industry organization International Society for Cell and Gene Therapy (ISCT).

● At the beginning of May, the company announced that a recently published clinical study showed promising results for mesenchymal stromal cells (MSCs) in the treatment of mild Alzheimer's disease. The study is a phase 2a study and is published in Nature Medicine (Rash et al., 2025) The results strengthen the scientific basis for NextCell's drug candidate ProTrans, which is being developed for autoimmune and inflammatory diseases.

● NextCell announced in mid-May that Eric Strati PharmD, MBA, joins NextCell's Board of Advisors to support the commercial strategy for ProTrans

● In mid-May, NextCell announced that it had entered into a strategic partnership with Fujifilm Irvine Scientific Inc. to bring together their core competencies in mesenchymal stromal cells (MSCs) and life science raw materials. The goal of the collaboration is a comprehensive offering to researchers, biotech and pharmaceutical companies in the cell therapy field – standardized MSC products, optimized cell culture and solutions for cryopreservation.

● At the end of May, the company announced that it hadbeen granted a US patent for the MSC prediction algorithm. The patent protects NextCell's innovative method for predicting the effect of treatment with mesenchymal stromal cells (MSCs) in individual patients and for developing individualized treatment options based on this prediction.

● At the end of May, the company further announced that Angela Vollstedt, PhD, MBA, will join NextCell's Board of Advisors to strengthen the company's strategy for manufacturing and licensing.

Significant events and news after the reporting period

● At the beginning of June, the Company announced the outcome of the exercise of TO2 and resolved on directed share issues to guarantors, Through the exercise of the Warrants and the Directed Issue, the Company will receive a total of approximately SEK 36.6 million before deduction of issue costs. Furthermore, the Board of Directors has resolved on a set-off issue of 1,742,100 shares to the guarantors for payment of the guarantee fee.

● The Company announced in early June that all patients in the ongoing ProTrans-Young clinical study had been treated. A milestone that marks the completion of dosing in the company's largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the company's lead cell therapy candidate, ProTrans, for the treatment of children and adolescents with newly diagnosed type 1 diabetes.Cell and Gene Therapy (ISCT).

● In Mid-July the company summoned to an Extra General Meeting on August 21^st in order to change the company's fiscal year to be aligned with the calendar year.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 24-07-2025 07:00 CET.